LivaNova (NASDAQ:LIVN) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a report released on Wednesday.
Several other brokerages have also recently weighed in on LIVN. Needham & Company LLC increased their price target on LivaNova to $93.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. Canaccord Genuity reissued a “hold” rating and issued a $76.00 price target on shares of LivaNova in a research note on Tuesday, December 5th. Piper Jaffray Companies reissued a “buy” rating and issued a $85.00 price target on shares of LivaNova in a research note on Friday, November 3rd. BidaskClub cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research raised LivaNova from a “hold” rating to a “buy” rating and set a $89.00 target price for the company in a research note on Thursday, November 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $79.71.
Shares of LivaNova (NASDAQ:LIVN) opened at $78.48 on Wednesday. The firm has a market capitalization of $3,890.67, a PE ratio of 23.26, a PEG ratio of 2.42 and a beta of 0.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. LivaNova has a one year low of $44.58 and a one year high of $88.56.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $80.80, for a total transaction of $80,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alfred J. Novak sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The disclosure for this sale can be found here. Insiders have sold 6,830 shares of company stock valued at $569,350 in the last ninety days. 0.28% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. boosted its holdings in LivaNova by 9.8% in the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after acquiring an additional 153 shares in the last quarter. Riverhead Capital Management LLC boosted its holdings in LivaNova by 76.3% in the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock worth $108,000 after acquiring an additional 763 shares in the last quarter. Teacher Retirement System of Texas bought a new position in LivaNova in the second quarter worth approximately $204,000. Shelton Capital Management bought a new position in LivaNova in the third quarter worth approximately $209,000. Finally, Bessemer Group Inc. bought a new position in LivaNova in the second quarter worth approximately $220,000. 86.00% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “LivaNova (LIVN) Rating Lowered to Hold at ValuEngine” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.com-unik.info/2017/12/22/livanova-livn-rating-lowered-to-hold-at-valuengine.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.